Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer

Postmenopausal patients with hormone-sensitive early breast cancer are typically treated with adjuvant endocrine therapy, which significantly reduces the risk of recurrence. Because treatment is of a long duration, side effects from adjuvant therapy can be problematic. The aromatase inhibitors (AIS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehdev, S., Martin, G., Sideris, L., Lam, W., Brisson, S.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2009
Materias:
Medical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722047/
https://www.ncbi.nlm.nih.gov/pubmed/19672417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722047/
https://www.ncbi.nlm.nih.gov/pubmed/19672417

Ejemplares similares